The Medicines and Medical Devices Bill seeks to address safe medical regulation. Due to Brexit the current collaborative approach between the UK and the EU ending will have a huge impact on life sciences and pharmaceutical industries. Issues that may arise are different licensing arrangements for medicines in the UK from the EU.
Lord Rennard calls for a close alignment for regulation between the UK the EU and other international standard bodies. There is a concern that patients in the UK will be accessing the latest innovations significantly later than patients in the EU.
Watch the whole agenda in the House of Lords.
See archived appearances in parliament.